The registry component of the study is remarkable in its completeness. The researchers linked several Finnish national health registries, including the Medical Birth Registry, the Hospital Discharge Registry, the National Drug Purchase Registry and the Kanta laboratory archive, covering 965,312 children born between 1998 and 2014. Because Finland maintains comprehensive, automatically recorded records of hospitalisations and reimbursed prescription purchases, the investigators could follow virtually the entire national birth cohort through age seven, with descriptive follow-up extended to age twelve. Severe infant RSV was defined as inpatient hospitalisation with microbiologically confirmed RSV during the first year of life, while childhood recurrent wheezing or asthma was captured through a special national reimbursement status that requires physician-verified diagnostic criteria and six months of regular anti-inflammatory inhaled therapy.

Among the full cohort, 1.5 percent of children were hospitalised with RSV during infancy and 3.7 percent received the asthma medication reimbursement between ages one and seven. The crude risk of recurrent wheezing or asthma was 3.71 times higher after infant RSV hospitalisation. But the clinical trajectory of RSV-associated wheezing looked distinctly different from wheezing without prior RSV. Children whose asthma followed infant RSV hospitalisation started inhaled corticosteroid treatment earlier, at a mean age of 2.27 years versus 3.35 years, and used substantially more inhaled steroids between ages one and two. After age five, however, the pattern reversed: children with RSV-associated disease purchased fewer inhaled corticosteroids than their non-RSV counterparts, indicating earlier discontinuation and potentially a more transient disease course.

Laboratory data added a further biological clue. Among more than 77,000 children with recorded blood eosinophil measurements, those with RSV-associated recurrent wheezing or asthma had significantly lower median eosinophil counts than children with wheezing but no infant RSV hospitalisation, 0.341 versus 0.398 cells per litre, with the divergence most pronounced between ages three and eight. Because eosinophils are hallmark cells of allergic, type 2–driven inflammation, this pattern suggests that wheezing following severe infant RSV is less connected to allergic sensitisation. It aligns with birth cohort evidence that early-life RSV is associated with a resolving, non-atopic wheeze phenotype rather than the persistent eosinophilic asthma that dominates later childhood.

The sibling analysis addressed the confounding problem that has plagued observational studies for decades. Full siblings share parents, household environment and roughly half their genes, so comparing siblings discordant for RSV hospitalisation largely controls for shared familial factors. The researchers identified 263,888 full-sibling pairs and examined 15,667 pairs discordant for recurrent wheezing or asthma. In conditional logistic regression adjusted for sex, gestational age, birth month, birth year, caesarean delivery, maternal smoking and birth order, RSV hospitalisation in the first year of life remained strongly associated with later recurrent wheezing or asthma, with an odds ratio of 2.76. The association held across every stratum of parental asthma status, and antibiotic purchase rates, used as a proxy for general infection susceptibility, were nearly identical between the discordant siblings, arguing against a broadly infection-prone constitution as the explanation.

Intriguingly, the unaffected siblings in RSV-discordant pairs had roughly twice the population-average rate of recurrent wheezing or asthma, revealing an elevated baseline familial susceptibility in families affected by severe infant RSV. This points to a mixed model: inherited predisposition and shared environment raise the likelihood of both severe RSV and asthma in these families, while severe RSV itself appears to contribute an additional, independent excess risk on top of that baseline. The result is consistent with mechanistic literature describing airway injury and longer-lasting immune skewing after RSV infection, but it also suggests that familial factors explain part of the epidemiological signal that earlier studies attributed wholly to the virus.

To probe the genetic architecture, the team conducted a genome-wide association study meta-analysis of early-life RSV infection across Finnish, Swedish and Danish cohorts, including FinnGen, the Child and Adolescent Twin Study in Sweden and the Danish Blood Donor Study, together with previously published GWAS summary statistics. The analysis encompassed 3,107 RSV cases and 92,091 controls and identified a single genome-wide significant locus on chromosome 10, with the lead variant rs787036, an intronic single nucleotide polymorphism within the gene APBB1IP. This gene encodes RIAM, a regulator of integrin activation that governs immune-cell adhesion, trafficking and signalling, and is highly expressed in lymphoid tissues. The association replicated in the Norwegian Mother, Father and Child Cohort Study of 63,341 genotyped children, where both the lead variant and an RSV polygenic score were associated with parental report of lower respiratory tract infection by six months of age.

Crucially, the RSV susceptibility locus was not associated with asthma, and the reverse question fared no better. Using 155 independent, genome-wide significant asthma variants as genetic instruments, the researchers performed two-sample Mendelian randomisation and found no statistically significant evidence that genetic liability to asthma causally increases RSV susceptibility, with an inverse-variance-weighted odds ratio of 1.04. Sensitivity analyses using childhood-specific asthma variants and tests for directional pleiotropy were consistently null. Together, these genetic results indicate that shared common-variant asthma liability is unlikely to explain why some infants develop severe RSV, redirecting attention toward other early-life immune, airway and environmental determinants of disease severity.

The findings arrive at a pivotal moment for RSV prevention. A maternal RSV vaccine and two long-acting monoclonal antibodies, nirsevimab and clesrovimab, have recently become available, and immunisation programmes are being rolled out across high-income countries. Yet randomised prophylaxis trials to date have not demonstrated a reduction in childhood asthma, a puzzle the new study helps to frame. Because the interventions prevent severe disease rather than infection itself, and because RSV-associated wheezing appears concentrated in the first years of life and less tied to allergic asthma, the appropriate policy question shifts from whether RSV causes asthma to which long-term respiratory outcomes are plausibly preventable, and in whom. The authors argue that post-RSV follow-up and immunisation trials should focus on early-childhood symptom burden and treatment trajectories rather than assuming uniform, persistent asthma.

The study carries limitations worth noting. Registry-based exposure captures only severe infant RSV requiring hospitalisation, so milder infections in the comparison group likely attenuate effect estimates, and inference is restricted to severe early-life disease. The reimbursement endpoint is clinically anchored but strict, potentially missing milder wheezing phenotypes, and the sibling design reduces but cannot eliminate residual non-shared confounding. The genetic analyses remain modest in case numbers, and the predominantly Nordic, European-ancestry participants limit generalisability to other populations and RSV epidemiological settings. Nevertheless, by integrating population-scale phenotyping, within-family comparison and genome-wide analysis with independent replication, the study delivers the clearest picture yet of the RSV–asthma relationship and identifies APBB1IP as a compelling target for larger, harmonised genetic and mechanistic investigations of severe infant RSV.

Subject of Research: The relationship between infant respiratory syncytial virus infection and childhood asthma, examined through nationwide registry data, sibling-controlled analysis and genome-wide association study.

Article Title: Infant respiratory syncytial virus and childhood asthma: a nationwide registry-based, sibling-controlled, and genome-wide association study

Article References: Vartiainen, P., Haapaniemi, H., Lee, Y., Magnus, M. C., Hartonen, T., Detrois, K., Viippola, E., Ferro, M., Laitinen, T., Madsen, M. A., Ostrowski, S. R., Pedersen, O. B., Sørensen, E., Erikstrup, C., Gong, T., Rhedin, S., Lundholm, C., Dallagiacoma, G., Almqvist, C., … Heinonen, S. (2026). Infant respiratory syncytial virus and childhood asthma: a nationwide registry-based, sibling-controlled, and genome-wide association study. The Lancet Regional Health – Europe, 70, Article 101836. https://doi.org/10.1016/j.lanepe.2026.101836

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101836

Keywords: RSV, asthma, recurrent wheezing, genome-wide association study, Mendelian randomisation, sibling comparison, Finnish registries, APBB1IP, bronchiolitis, RSV immunisation, eosinophils, childhood respiratory disease